New Phase II Trial Data Support Low-Dose Deferasirox for Anemia in Low-Risk MDS
Vibecotamab Shows Promise in High-Risk Myeloid Diseases
Early Signs of Activity Observed for Tagraxofusp Plus Decitabine in MDS, CMML